Phillip A. Furman, Ph.D. - Vice President, Biological SciencesPhillip A. Furman, Ph.D. is our Vice President, Biological Sciences and has been with Pharmasset since February 2004.From October 2001 to February 2004, Dr. Furman was a consultant for Bukwang Pharm.Co., Ltd.
and other organizations.Prior to joining Pharmasset, Dr. Furman was a co-founder and the Chief Scientific Officer of Triangle Pharmaceuticals, an antiviral drug discovery and development company, which was acquired by Gilead Sciences.
While at Triangle
from 1995 to October 2001, he
oversaw the activities of the virology group and reviewed antiviral and anticancer licensing candidates.During his 20-plus year tenure in drug discovery and development with Burroughs Wellcome, most recently as the Director of the Division of Virology from 1989 to 1995, Dr. Furman was a co-inventor of the use of Retrovir for the treatment of HIV and Epivir for the treatment of HBV.He
has also been involved in the clinical development of numerous antiviral agents, including Zovirax (acyclovir), Retrovir
, Emtriva, Ziagen, Agenerase (amprenavir) and Viroptic (trifluridine).Dr. Furman is an author of over 80 scientific publications, and he is named as an inventor on more than 20 patents.Dr. Furman received a B.S. in Biology and Chemistry from Piedmont College, an M.A. in Microbiology from the University of South Florida, and a Ph.D. in Microbiology from Tulane University.